Login to Your Account



TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's

By Nuala Moran
Staff Writer

Monday, September 10, 2012

LONDON – TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease.

The study in Pick's, or behavioral-variant frontotemporal dementia (bvFTD), is due to be followed by a Phase III trial of LMTX in Alzheimer's. Funding for both trials is in place.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription